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A B S T R A C T
Lycopene is a bioactive component mainly found in tomato. It is characterized by a high antioxidant potential,
the highest among carotenoids. Mainly due to this property, lycopene has been suggested to display many
beneficial effects, including its potential cardioprotective role. Despite some contradictory observations, which
appear to be mainly caused by discrepancies in the different experimental protocols applied in the different
studies, growing evidence points to clear benefits of lycopene in the maintenance of cardiovascular function and
health. The knowledge about lycopene’s preventive effects in atherosclerosis, and other cardiovascular diseases,
must be translated into changes in food patterns, aiming to increase the consumption of tomato, tomato-con-
taining products, or other foods with high lycopene content, which can have an important impact on cardio-
vascular disease, particularly in countries where this represents a major public health concern.
1. Introduction
Unhealthy food ingestion is a major cause of numerous pathologies,
among which are cardiovascular diseases. This group of diseases, which
represent the leading cause of death and incapacity worldwide are
mainly caused by dysregulated plasma lipid levels, pro-inflammatory
status and excessive production of reactive oxygen species (Gonzalez &
Selwyn, 2003). In this context, there are many molecules, some of them
not required for human biochemistry and metabolism, which may
confer cardioprotection and lower the risk of cardiovascular disease.
Among them, antioxidants appear to have a high potential and have
been implicated in such protection (Petyaev, 2016).
Lycopene belongs to the family of the lipid-soluble antioxidants
called carotenoids, which are present in fruits and vegetables (El-
Agamey et al., 2004; Tapiero, Townsend, & Tew, 2004). Although ly-
copene can be found in many other fruits and vegetables, it is mainly
found in tomatoes, or tomato-containing products, which account for
about 80% of total lycopene ingestion (Bohm, 2012; Moran, Erdman, &
Clinton, 2013). Besides being the carotenoid with the highest anti-
oxidant potential, lycopene has also the ability to modulate several key
events that are important in the context of cardiovascular diseases, such
as inflammation, apoptosis or cellular communication (Thies, Mills,
Moir, & Masson, 2017). The main disadvantage of lycopene is related to
its low bioavailability, which depends not only on the different lyco-
pene biochemical isoforms, but also on the context of ingestion and on
the genetics of each individual (Borel, Desmarchelier, Nowicki, & Bott,
2015; Petyaev, 2016; Zubair et al., 2015). The sum of these variables
may account for some of the contradictory information regarding the
real effects of lycopene in cardiovascular disease protection. Never-
theless, growing evidence points to robust benefits of lycopene intake,
which will be discussed in the present review.
2. Biochemical properties of lycopene
Carotenoids are coloured lipid molecules mainly found in vegetable
products, such as fruits, leaves, tubers or roots (El-Agamey et al., 2004;
Tapiero et al., 2004). They can be divided into three groups, namely,
carotenes, xanthophylls and lycopene (Jomova & Valko, 2013; Rutz,
Borges, Zambiazi, da Rosa, & da Silva, 2016). Globally they present
antioxidant properties, and although only a few are indispensable for
humans, they are considered very important dietary bioactive compo-
nents. There are more than 700 different carotenoids found in nature,
but only six of them are found in significant amounts in human serum,
namely, α-carotene, β-carotene (Fig. 1), β-cryptoxanthin, zeaxanthin,
lutein and lycopene (Maiani et al., 2009). Biochemically they are iso-
prenoid compounds with a tetraterpene structure (Kaulmann & Bohn,
T
2014). The majority present a central carbon chain with conjugated
double bonds and various cyclic or acyclic groups (Stahl & Sies, 2005).
Although it was originally isolated from black bryony, lycopene is
particularly abundant in tomato (Milani, Basirnejad, Shahbazi, &
Bolhassani, 2016), but it is also found in several other food resources,
such as pepper, papaya, watermelon, carrots, pink guava and grapefruit
(Assis et al., 2017; Milani et al., 2016). It is a lipophilic molecule with
13 double bonds, which include 11 that are conjugated (Fig. 1)
(Petyaev, 2016). In nature, all the double bonds are found in the trans
configuration (Jackson, Braun, & Ernst, 2008). Exposure to light, di-
gestion and thermal processing of lycopene promotes trans-to-cis iso-
merization (Fig. 1) (Moise, Al-Babili, & Wurtzel, 2014). This transition
is believed to be important to increase the efficiency of its intestinal
absorption, a process thought to be mediated by SR-BI but not NPC1L1
membrane transporter (Moussa et al., 2008; Schweiggert et al., 2014).
Lycopene’s open-polyene chain, without the ionone ring found in β-
carotene, confers this molecule with a very high antioxidant capacity,
which is significantly higher than that of other carotenoids, namely,
more than twice that of β-carotene and about 10 times higher than that
of α-tocopherol (Engelmann, Clinton, & Erdman, 2011; Milani et al.,
2016). It is particularly effective in the quenching of superoxide anion
free radicals, although the cis-isoforms are also very effective against
peroxyl radicals (Engelmann et al., 2011; Jackson et al., 2008). Al-
though the antioxidant properties of lycopene are well-known, the
exact mechanism of action remains to be elucidated (Zhang, Liu, & Lv,
2016). Serum levels are strongly dependent on the intake of tomato
products (Allen et al., 2003; Ganji & Kafai, 2005), and it is the most
abundant carotenoid found in serum in Americans and the second in
Europeans (Erdman, Ford, & Lindshield, 2009; Jenab et al., 2005).
Its half-life in humans also depends on the configuration of the
conjugated double bonds, being 5.3 and 8.8 days for all-trans and all-cis
isomers, respectively (Moran et al., 2015). One of the main obstacles,
when considering the biological effects of lycopene, is its very low and
variable bioavailability, which depends on the combination of at least
twenty-eight single nucleotide polymorphisms (Borel et al., 2015;
Zubair et al., 2015). Other factors accounting for this situation include
the configuration of the double bonds, the geographic location of in-
dividuals, other sociodemographic factors, health status and, obviously,
the food ingestion context (Petyaev, 2016). This high complexity may
account, at least partially, for the elevated inter-individual variability of
lycopene concentrations and biological effects. Moreover, lycopene
distribution throughout the human body is asymmetrical, being mostly
found in liver, adrenals, lungs, prostate and skin (Moran, Clinton, &
Erdman, 2013).
Plasma levels of lycopene are very different among different popu-
lations and may reflect not only the endogenous properties of each
individual, but, as previously mentioned, the diet. Globally, Northern
and Western Europe along with America seem to be the regions with the
lower ingestion of lycopene, while Asia and Central Africa appears as
the region with the highest values (Murphy, Barraj, Spungen, Herman,
& Randolph, 2014). The main dietary source of lycopene, worldwide, is
tomato (a significantly higher intake than carrots); however, in Asia,
lycopene comes mainly from watermelon (∼50%), but also from to-
matoes (∼30%). Regarding the high plasma levels of lycopene found in
Asia, it is important to highlight that that region is becoming one of the
largest worldwide tomato producers, which may account for the ob-
served plasma levels. Furthermore, it is estimated that tomato con-
sumption accounts for 10–20% of the total vegetal consumption in the
Pacific region of Asia. Also, metabolic relationships on the bioavail-
ability and utilization of lycopene, as well as lifestyle, may contribute to
the observations highlighted before, significantly accounting for the
differences observed in lycopene plasma values among the world.
Lycopene has the potential to modulate many different cellular
processes. There are multiple forms by which it can act in target cells
Fig. 1. Chemical structure of β-carotene, lyco-
pene and its isomers obtained by thermal pro-
cessing and light exposure.
(Feitelson et al., 2015; Friedman, 2013; Thies et al., 2017). It was ob-
served that lycopene can promote apoptosis and inhibit cell prolifera-
tion both in vitro and in vivo (Gupta, Bansal, & Koul, 2013; Uppala,
Dissmore, Lau, Andacht, & Rajaram, 2013). Also, it is able to stimulate
cell differentiation in vitro, particularly due to a positive effect in gap
junction communication (Stahl, von Laar, Martin, Emmerich, & Sies,
2000). Other important mechanisms of action of lycopene include the
inhibition of angiogenesis and oxidative damage, and the stimulation of
phase II enzymes expression and activity, both in vitro and in vivo (Chen,
Lin, Yang, & Hu, 2012; Lian & Wang, 2008; Palozza, Simone, Catalano,
Russo, & Bohm, 2012). Also, as discussed below, lycopene have the
ability to modulate inflammation, which may account for its health
potential benefits.
Since oxidative stress has been linked to numerous pathological
conditions, carotenoid ingestion, and, particularly, lycopene consump-
tion, is associated to a decrease in the risk of chronic conditions such as
inflammatory disorders, cancer, gastrointestinal, cardiovascular and
neurodegenerative diseases, as well as to an increase in the immune
system function (Ghavipour et al., 2013; Lorenz et al., 2012; Milani
et al., 2016). Nevertheless, as highlighted in the present review, the
mechanisms of action of lycopene lay far beyond its antioxidant prop-
erties and, thus, the potential effects of lycopene on human cells are
multiple.
3. Pathophysiology of cardiovascular disease
Cardiovascular diseases are the main cause of mortality and mor-
bidity around the world. They present a complex pathogenesis, the
majority of them being caused by ischemic events and, globally, they
can be considered as the result of a sum of different complementary
factors, such as increased blood lipid levels and blood pressure, as well
as endothelial dysfunction (Gonzalez & Selwyn, 2003). Although
nowadays there are numerous technical interventions that can be
conducted in order to treat patients, such as coronary bypass surgery,
thrombolysis, or angioplasty (Tong et al., 2016), special attention must
be taken regarding primary prevention, since this group of diseases is
mainly caused by modifiable risk factors. Among them, perhaps the
most important one is diet. It is well-known that Mediterranean coun-
tries have a lower rate of cardiovascular disease mortality (Garcia-
Fernandez, Rico-Cabanas, Rosgaard, Estruch, & Bach-Faig, 2014),
which is at least partially attributable to the healthy eating lifestyle.
The so-called Mediterranean diet is based on the ingestion of high
amounts of fresh fruit and vegetables, with one of the most ingested
being the tomato (Petyaev, 2016).
In the context of cardiovascular ischemic diseases, it is also im-
portant to considerer that reperfusion after prolonged ischemia may
lead to myocardial injury, which, in turn, can cause infarct expansion
and/or arrhythmias (Tong et al., 2016). However, either in the case of
the initial lesion, or in the case of reperfusion lesions, oxidative stress
appears to have a central role (Tong et al., 2016). Thus, high anti-
oxidant levels, including those of lycopene, may contribute in pre-
venting or, at least, decreasing, the extent of these lesions.
Cardiovascular diseases have a complex pathophysiology, with
several parameters critical for their development and, consequently, for
the clinical outcome. The main parameters are summarized in Table 1.
One key event in the development of the vast majority of cardiovascular
diseases is the oxidation of low density lipoprotein (LDL) (Aviram,
1993; Steinberg & Witztum, 2010). Its accumulation in the sub-en-
dothelial space, and further recognition by the scavenger receptors
found on the surface of macrophages, causes the formation of foam
cells, which are characteristic of the atherosclerotic lesions. Besides this
important role in the pathogenesis of atherosclerosis, oxidized LDL also
promotes endothelial dysfunction, increases the production of super-
oxide anion radical and the remodeling of the smooth muscle layers on
vascular walls (Galle, Hansen-Hagge, Wanner, & Seibold, 2006). In this
context, the high antioxidant potential of lycopene may account for a
decrease in LDL oxidation and, thus, decrease the risk of cardiovascular
disease. For the other two parameters (blood pressure and flow-medi-
ated dilation), the action of NO as a key vasodilator appears to be
strongly dependent on the redox status of the cellular environment,
since the endothelial-derived free radicals may neutralize it. So, lyco-
pene, as well as other antioxidants, may have an important role in the
prevention of excessive NO neutralization and, consequently, in the
maintenance of a proper vessel diameter. Taken together, there are
numerous factors involved in the genesis and development of cardio-
vascular diseases, and the majority of them seem to have the potential
for being modulated by bioactive compounds, including lycopene.
4. Cardioprotective properties of lycopene
4.1. Controversies
Due to the complex nature of cardiovascular disease, many dietary
phytochemical properties have been suggested to play an important
role in cardiovascular protection. For example, the consumption of ni-
trate-rich food, due to its potential to increase NO plasma levels, has
been linked to improvements in endothelial integrity and function (Lara
et al., 2016) and also to a decrease in blood pressure (Siervo, Lara,
Ogbonmwan, & Mathers, 2013). Also, dietary antioxidants, such as
carotenoids, appear to be potential key players in the prevention of
cardiac and vessels pathologies (Mozaffarian, Appel, & Van Horn,
2011). In line with this, in a meta-analysis of sixteen cohort studies,
involving more than 800,000 subjects, it was observed that the mor-
tality associated with cardiovascular disease is lowered by a higher
consumption of fruit and vegetables, namely, up to five servings/day
(Wang et al., 2014). This effect appeared to be sensitive to the number
of servings.
Since among carotenoids, lycopene is the one with the highest an-
tioxidant potential, generally it has been linked to a decrease in car-
diovascular disease risk (Jacques, Lyass, Massaro, Vasan, & D'Agostino,
2013; Sesso, Liu, Gaziano, & Buring, 2003; Yeo, Kim, Lim, Kim, & Lee,
2011). Although theoretically this relationship is consistent with the
knowledge of the impact of oxidative stress in cardiovascular disease,
and there is growing evidence that points that way (Table 2), in practice
it remains, at least in some aspects, controversial.
Although the majority of the studies are favourable to positive ef-
fects of lycopene on cardiovascular health, there are also several studies
that have failed to prove a consistent relationship between lycopene
intake and a decreased risk of cardiovascular disease markers or out-
come (Li & Xu, 2014; Osganian et al., 2003; Sesso et al., 2003; Tavani,
Table 1
Impact of different cardiovascular parameters on cardiovascular disease.
Cardiovascular parameter Normal healthy levels Cardiovascular disease outcome
LDL levelsa) < 2.6 mM Reduction of 1 mM elicits a decrease of 23% in the risk of occurrence of myocardial infarction and 12% in all-cause mortality
Blood pressureb) < 120/80mmHg Reduction of 5mmHg cause a decline in cardiovascular disease mortality of about 9%, with a decrease of 13–14% in the case
of stroke
Flow-mediated dilationc) 7–10% Increase of 1% causes a reduction of 10–13% in the risk of cardiovascular pathological events
a) Baigent et al., 2005/b) Chobanian et al., 2003; Reboldi et al., 2011/c) Matsuzawa, Kwon, Lennon, Lerman, & Lerman, 2015; Xu et al., 2014.
Gallus, Negri, Parpinel, & La Vecchia, 2006; Thies et al., 2017). These
include human intervention studies, prospective studies, and retro-
spective studies. There might be many different reasons underlying
these negative associations. As stated above, lycopene bioavailability
and metabolism is strongly influenced by genetic variability, being
described at least 28 single nucleotide polymorphisms in 16 genes,
among which are those coding for the cholesterol membrane trans-
porter scavenger receptor class B, member 1 (SCARB1), the molecular
guidance cue slit homolog 3 gene (SLIT3) and the steroid-breakdown
enzyme dehydrogenase/reductase (SDR family) member 2 (DHRS2)
(Borel et al., 2015; Zubair et al., 2015) and, thus, results would be
significantly influenced by this issue. Also, the cardiovascular markers
used in the different studies varied significantly (ranging from bio-
chemical parameters such as LDL levels or blood pressure, to clinical
outcomes like occurrence of myocardial infarction, stroke or death)
which makes detailed comparisons among them difficult. The varia-
bility found in the lycopene sources (ranging from fresh tomatoes to
processed tomatoes, tomato-containing foods or even lycopene sup-
plements), lycopene doses, ingestion of foods containing other com-
pounds that may potentiate or decrease lycopene effects and duration of
the experiments, may also account for some of the observed dis-
crepancies. Furthermore, many published works used less than 100
volunteers, which decreases their statistical power and, thus, caution is
required in the interpretation and extrapolation of the results. Knowing
in advance that there are no perfect experimental protocols, it is re-
commended that future retrospective experiments should be conducted
with large populations (preferably from the same geographic location,
in order to avoid a high genetic variability), if possible framed in co-
horts well-characterized from a food pattern point of view. At the same
time, prospective studies, in which the amount and processing of to-
matoes ingested are strictly controlled, may be informative at the level
of possible biochemical alterations that decrease or increase the risk of
developing cardiovascular disease. In this case, special attention must
be paid to the experimental period, since lycopene ingested prior to the
start of the study may persist in the body for a significant time. Thus, a
period of washout of lycopene from previous ingestion is re-
commended.
4.2. Lycopene and cardiovascular risk factors
Recently, the impact of lycopene supplementation in cardiovascular
disease risk factors was reviewed (Burton-Freeman & Sesso, 2014).
Once again, the different experimental protocols found in the different
studies caused difficulties in the comparison of results, but it appeared
that the consumption of lycopene-containing food may be more
effective than the use of lycopene supplements. This is probably due to
the presence of other important compounds in tomato products, such as
bioactive molecules and also electrolytes, that may potentiate the ly-
copene bioavailability and the lycopene-related effects (Friedman,
2013). In another recent study, an inverse association was observed
between lycopene consumption and the incidence of ischemic heart
disease, as well as coronary insufficiency, which is in line with the
previous findings (Riccioni et al., 2009; Wolak & Paran, 2013).
In a randomized trial performed with 225 volunteers, the authors
were unable to demonstrate significant effects of lycopene consump-
tion, from tomato-containing food, on conventional inflammatory,
vascular and lipid markers. However, lycopene elicited an improvement
in high density lipoprotein (HDL) functionality (Thies et al., 2012).
4.3. Lycopene and cardiovascular function
Recently, a systematic review and meta-analysis was conducted,
concerned with the effects of lycopene and cardiovascular function
(Cheng et al., 2017). Only interventional studies with human subjects
with dietary exposure to tomato-based products or lycopene supple-
ments were considered, giving a total of twenty-two publications.
Globally, it was observed that not only did lycopene appear to elicit a
decrease in plasma LDL-cholesterol levels, but also an increase in en-
dothelial function. Regarding the former effect, it is important to
highlight that once again, only lycopene-containing foods, but not ly-
copene supplements, were able to promote it. Furthermore, a decrease
in blood pressure (both systolic and diastolic), triglycerides, in-
flammation and adhesion markers, as well as an increase in HDL-cho-
lesterol, also seemed to be linked to a high ingestion of lycopene-con-
taining food/supplements, although in this case, the evidence was not
so robust (Cheng et al., 2017). These results are in line with previous
meta-analysis studies in this area (Li & Xu, 2013; Ried & Fakler, 2011).
Interestingly, important differences among different countries were also
highlighted, which suggests that the geographic context and culture
may also modulate the cardioprotective effects of lycopene (Cheng
et al., 2017; Li & Xu, 2013; Ried & Fakler, 2011).
In a recent meta-analysis study, aiming to evaluate the relationship
between lycopene intake, its plasma levels and cardiovascular disease,
it was observed that lycopene was associated with a 17% reduction in
the risk of cardiovascular disease, when comparing the highest ana-
lyzed intake with the lowest one (Song et al., 2017), The reduction of
cholesterol levels and inflammatory response, the decreased oxidation
of biomolecules, the improvement of intercellular communications and
stimulation of apoptosis and the antiangiogenic effects were among the
proposed mechanisms involved in lycopene’s cardiovascular protective
effects. The effects on cholesterol levels may be attributable to different
actions, like inhibition of cholesterol synthesis and modulation of LDL
receptor and intracellular storage of cholesterol (Palozza, Catalano,
Simone, Mele, & Cittadini, 2012).
4.4. Lycopene and inflammation
The anti-inflammatory effects of lycopene have been linked to nu-
merous ways in which this molecule can modulate cellular activities.
High lycopene levels seemed to be inversely related with arterial
thickness and, putatively, with the risk of atherosclerosis and/or stroke
(Karppi, Kurl, Ronkainen, Kauhanen, & Laukkanen, 2013). Also, it can
directly protect endothelial cells from oxidative damage, and inhibit
monocyte-endothelium interactions, as well as platelet aggregation
(Hung et al., 2008; Sawardekar, Patel, & Uchil, 2016). Furthermore,
lycopene may suppress the oxidative response of neutrophils, as well as
the secretion of pro-inflammatory cytokines (Marcotorchino et al.,
2012; Zou, Feng, Ling, & Duan, 2013). The proliferation of smooth
muscle cells, as well as monocytes and T-lymphocytes, also appear to be
downregulated by lycopene (Lo et al., 2007; Mills, Wilson, & Thies,
2012).
Table 2
Main cardiovascular protective effects of lycopene.
Effects Reference
↓ ischemic heart disease - Riccioni et al., 2009
↓ coronary insufficiency - Wolak & Paran, 2013
↑ HDL functionality - Thies et al., 2012
↓ plasma LDL-cholesterol levels - Cheng et al., 2017
↑ endothelial function
↓ risk of cardiovascular disease - Song et al., 2017
↓ arterial thickness - Karppi et al., 2013
↓ risk of atherosclerosis and/or stroke
↑ protection of endothelial cells from oxidative
damage
- Hung et al., 2008
↓ monocyte-endothelium interactions - Sawardekar et al., 2016
↓ platelet aggregation
↓ oxidative response of neutrophils - Marcotorchino et al., 2012
↓ secretion of pro-inflammatory cytokines - Zou et al., 2013
↓ proliferation of smooth muscle cells - Lo et al., 2007
↓ activation of monocytes and T-lymphocytes - Mills et al., 2012
↓ C-reactive protein levels in women - Biddle et al., 2015
↑ vasodilation mediated by endothelial cells - Gajendragadkar et al., 2014
In a study conducted with heart failure patients, lycopene con-
sumption promoted a decrease in C-reactive protein levels in women,
but had no significant effect in men (Biddle et al., 2015). In another
study, lycopene supplementation was able to improve vasodilation
mediated by endothelial cells, in cardiovascular disease patients, while
in the healthy control patients, no significant effect was observed
(Gajendragadkar et al., 2014), suggesting that lycopene may be parti-
cularly effective as a secondary prevention player.
Thus, although lycopene presents a very high antioxidant activity,
at least in some cases its role in cardiovascular protection appears to be
more related to its anti-inflammatory properties, than to the inhibition
of the oxidation of LDL, since lycopene, due to its elevated hydro-
phobicity, is more likely to be found in the nuclear hydrophobic core of
the lipoprotein (Muller, Caris-Veyrat, Lowe, & Bohm, 2016). Never-
theless, it was proposed that the consumption of one or more servings/
day of tomato-rich products is related to a lower risk (30%) of cardio-
vascular disease (Sesso et al., 2003). Quantitatively, the cardioprotec-
tive effects of lycopene seemed to be relevant following 1–180 days of
tomato-products ingestion (70–400 g/day) (Cheng et al., 2017). For
comparison, the average consumption of lycopene ranges between 5
and 7mg/day in the developed countries, which corresponds to ∼50 g
of tomato-products (Wang, 2012).
It is important to note that the conflicting results about the potential
cardioprotection elicited by lycopene may be related to the wide variety
of experimental protocols used to discover any association between
lycopene consumption and cardiovascular disease. These important
differences include the pre-existing levels of lycopene, the source of
lycopene (tomato products, supplements, etc.), the characteristics of the
target populations (healthy, unhealthy, smokers, non-smokers, etc.),
the amount of lycopene consumed, the duration of lycopene supple-
mentation and the analyzed markers/cellular effects. Interestingly, and
despite all the observed differences, it was proposed that total car-
otenoid levels may predict all-cause mortality and poor outcomes and
rapid progression of cardiovascular disease (Shardell et al., 2011). Al-
though, globally, carotenoids are not indispensable micronutrients,
they have very important biochemical features that make them useful
allies in promoting a good health status.
5. Conclusion
Despite some controversy about specific effects of lycopene in car-
diovascular protection, growing evidence points to unequivocal bene-
fits of lycopene intake both in terms of cardiac, endothelial and vascular
function and health. The underlying mechanisms by which lycopene
exerts its effects are now being unravelled, and might explain some of
the contradictions observed in the literature. The genetic inter-in-
dividual differences may also be a key issue in understanding the real
effects of lycopene in each individual. The context of ingestion of ly-
copene also appears to be important, since globally the beneficial ef-
fects were more significant for the ingestion of food-containing lyco-
pene (particularly tomato products), than for lycopene supplements.
Thus, the ingestion of lycopene-containing food, may be relevant for the
prevention of atherosclerosis and other cardiovascular diseases and,
consequently, must be considered an important strategy, particularly in
countries where these diseases are a major public health concern. Also,
conditions that promote long-lasting oxidative stress, such as physical
exercise, smoking or chronic pathologies, may cause a significant de-
crease in lycopene levels, and, thus, an efficient replenishment of that
molecule may be required. Taken together, recommendations for ly-
copene intake must take into account not only its low bioavailability
and asymmetrical distribution throughout the human body, but also the
conditions that can accelerate the loss of lycopene. So, the establish-
ment of individualized nutritional approaches and recommendations
that consider all of these factors may have a profound impact on car-
diovascular disease and, consequently, on human health.
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